Health & Biotech
Vital Signs Podcast: Why this clinical-stage oncology company is “first in class”
Compumedics’ dual-helmet brain tech hits a nerve in China’s neuroscience boom
Neurizon inks global licensing deal with NYSE-listed Elanco
Health Check: Like bloodthirsty sharks, offshore acquirers are circling cheap biotech assets
EMVision makes progress in key trials for bedside brain scanner
Myriad soft-tissue reconstruction products position Aroa for strong growth
Biocurious: Dimerix could be riding big and beautiful kidney drug success earlier than expected
Health Check: And the EOFY biotech winner is … gasp … a pot stock
Optiscan begins breast cancer study in Melbourne
Trajan’s tech is enabling research into next-gen aviation fuels
Dr Boreham’s Crucible: ‘Better not louder’, Audeara is tuned in to the global audiology market
LTR Pharma completes study milestone for SPONTAN ED treatment
Health Check: Tetratherix breaks biotech IPO drought with 13pc gain on debut
Prescient advances new therapies for hard-to-treat cancers
Health Check: Paradigm makes scenic acquisitive detour, but it’s no strategic shift
Neurizon creates liquid formula to improve accessibility of ALS treatment
Health Check: UBS turns ultra-bullish on Aussie healthcare leaders
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.
